Abstract: Objective To investigate the effect of different doses of valsartan on ventricular vascular coupling index in patients with heart failure. Methods 400 patients with heart failure who were treated in our hospital from January 2020 to August 2022 were selected as the research objects. They were divided into the observation group (n=200, receiving 40 mg/d valsartan) and the control group (n=200, receiving 80 mg/d valsartan) according to the random number table method. The difference of the treatment effect between the two groups was compared, and the difference of the cardiac function index, myocardial injury index and adverse reaction rate index between the two groups before and after treatment was compared. Results The number of patients in the observation group was 80, and the number of patients in the observation group was 104. The total effective rate of the observation group slightly lower than that of the control group, but the difference was not significant(P>0.05); After treatment, LVEF and LVEDD of the two groups were significantly higher and lower than before treatment(P<0.05), but there was no significant difference between the two groups after treatment(P>0.05); After treatment, the levels of H-FABP and NT proBNP in the two groups were significantly lower than those before treatment(P<0.05). After treatment, the levels of NT proBNP in the control group were lower than those in the observation group(P<0.05); The total incidence of adverse reactions in the observation group was significantly lower than in the control group (P<0.05). Conclusion Valsartan is effective in improving the clinical symptoms of patients with heart failure. It can improve the heart function and alleviate the inflammatory state of patients. It is suggested that the dosage should be set at 40 mg/d. Increasing the dosage will not significantly improve the therapeutic effect, but will significantly increase the adverse reactions rate.

Key words: Valsartan, heart failure, Ventricular vascular coupling index, Dosimetry